UK Pharmacy
On this page you will find information for pharmacists involved in the RECOVERY Trial, including FAQs and HRA Pharmacy Assurance.
IMPORTANT NOTICES
February 2024: RECOVERY trial sotrovimab has received a further expiry date extension, to 48 months. Note the the sotrovimab comparison is due to close on 31 March 2024, so this only affects sites holding batch 2T8F (which had a previous expiry date of 29 Februrary 2024).
July 2023: RECOVERY trial sotrovimab has received a further expiry date extension, to 36 months. This will require relabelling existing stock. Please see sotrovimab 36 month expiry documents below.
June 2023: Following the closing of the molnupiravir and Paxlovid arms, sites should return any unused study drug to the site pharmacy for general use, following their local guidelines.